Postremission sequential monitoring of minimal residual disease by <scp>WT</scp>1 Q‐<scp>PCR</scp> and multiparametric flow cytometry assessment predicts relapse and may help to address risk‐adapted therapy in acute myeloid leukemia patients
Cancer medicine